Journal
EXPERT OPINION ON EMERGING DRUGS
Volume 20, Issue 2, Pages 331-346Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1517/14728214.2015.1036739
Keywords
angiogenesis; bevacizumab; fallopian tube cancer; ovarian cancer; primary peritoneal cancer; tyrosine kinase inhibitors; VEGF
Categories
Ask authors/readers for more resources
Introduction: Patients with epithelial ovarian cancer (EOC) have a high rate of recurrence, and overall survival remains at similar to 25%. There is a need for new treatments that can increase progression free survival and quality of life. Recent clinical trials focus on angiogenesis, VEGFs, and tyrosine kinase inhibitors that play a role in recurrence, metastasis, and ascites in EOC. Areas covered: This review summarizes clinical rationale, mechanisms of action, and clinical data for angiogenesis inhibitors under evaluation in Phase II and III trials for EOC. Anti-angiogenesis agents reviewed in this paper include aflibercept, bevacizumab, cediranib, fosbretabulin, imatinib, nintedanib, pazopanib, saracatinib, sorafenib, sunitinib, and trebananib. Expert opinion: These agents have particular rationale for potential use in EOC due to the molecular changes associated with EOC tumorigenesis, namely a significant increase in angiogenic activity. Due to the costs and toxicities associated with anti-angiogenics, biomarker or molecular signature selection strategy for patients who will most benefit would be ideal but no such strategy has been validated to date.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available